Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services, Scrap for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, the company has reported a Standalone Total ...

UNITED STATES – Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The ...

Pfizer plans to explore other obesity treatments for testing. Pfizer is halting the development of its potential pill for treating obesity following an injury that happened during a clinical trial.

Pfizer opens new tab on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury which resolved ...

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

Get the next trade alert free. Pfizer Inc. PFE is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.

Pfizer is ending development of its once-daily obesity pill danuglipron after a trial participant suffered possible liver injury. The decision halts early-stage testing and cancels plans for ...

Stocks like Pfizer, Amgen, Johnson & Johnson, and Eli Lilly & Co. were among others which opened lower after the US stock market opened on Wednesday. Pfizer Inc. shares are currently trading 2.56 ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

Pharmaceutical giant Pfizer sold its longtime San Diego campus to a life science-focused commercial real estate company in one of the largest deals of the past year. Pfizer sold the five ...